News Banner

MaxQ News

Posts about Vision:

Second Generation ACCIPIO Clinical Platform for the Healthcare

MaxQ Dec 3, 2020 5:30:00 PM

MAXQ AI LAUNCHES SECOND GENERATION ACCIPIO CLINICAL PLATFORM FOR THE HEALTHCARE INDUSTRY

Accipio V2 shipping now with enhanced functionality to accelerate physician adoption. AI deployments are accelerating throughout the COVID19 Pandemic

Tel Aviv, Israel – December 3rd, 2020 –  MaxQ AI, the industry-leading healthcare technology company that delivers comprehensive clinical workflow solutions assisting with improved patient triage and diagnosis, announced today it is now shipping the Accipio V2 Clinical Platform, including enhanced functionality to support seamless and secure integrations throughout its CT, PACS, radiology reporting, and curated AI partner base of global acute hospitals.

MaxQ AI Continues to Deploy Intelligence-Based Clinical Technology

MaxQ Nov 18, 2018 5:29:00 PM

MaxQ AI Continues to Deploy Intelligence-Based Clinical Decision Support Technology Across the Healthcare Industry

CHICAGO, IL – November 28, 2017 – Today, MaxQ AI announced its third industry engagement to bring MaxQ AI’s A.I.-based clinical decision support application to imaging experts working in hospital emergency rooms and other acute care settings.

MaxQ AI Receives FDA Clearance for Accipio Ix™

MaxQ Nov 7, 2018 4:18:00 PM

FDA Clearance for Accipio Ix™ Intracranial Hemorrhage Platform

Agreement will pave the way for integration of MaxQ AI’s artificial intelligence Accipio Ix™ intracranial hemorrhage software into NeuroLogica’s medical imaging platforms in the U.S. and E.U. acute care market

Tel Aviv, Israel and Andover, MA – November 7, 2018 – MaxQ AI, a clinical diagnostics intelligence platform company, today announced that its revolutionary Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance paves the way for healthcare providers and physicians in acute care settings to have access to this artificial intelligence (AI) software designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of intracranial hemorrhage (ICH), commonly known as a brain bleed.

MedyMatch Reveals Artificial Intelligence Deep Vision

MaxQ Nov 22, 2016 6:21:00 PM

Intracranial Bleed Detection Technology

Tel Aviv, Israel – November 22, 2016 – MedyMatch Technology Ltd., (“MedyMatch”) the deep learning and artificial intelligence company, announced today that after several years of extensive research and development, it has achieved a major milestone in the availability, for research, of an artificial intelligence-based technology that can help detect the presence of intracranial hemorrhage or brain bleed which can occur in cases of brain trauma and stroke. Subtle bleeds are difficult to detect and if misinterpreted or missed by a physician can lead to serious patient injury and even death.

Artificial intelligence healthcare startup MedyMatch launches

MaxQ Feb 17, 2016 5:47:00 PM

USES DEEP VISION AND COGNITIVE ANALYTICS TO INCREASE QUALITY OF CARE AND PATIENT OUTCOMES; FORMER PHILIPS IMAGING SYSTEMS CEO GENE SARAGNESE JOINS AS CHAIRMAN & CEO

Former Philips Imaging Systems CEO Gene Saragnese Joins as Chairman & CEO

Boston, MA, and Tel Aviv, Israel – February 17, 2016 – MedyMatch Technology, Ltd., the artificial intelligence healthcare startup, announced today its launch and vision to improve performance in healthcare with real-time decision support tools, starting in the Emergency Room. Additionally, the Company announced that Mr. Gene Saragnese joined as Chairman & Chief Executive Officer.